Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia

Journal of Clinical Investigation

Volumn 98, Issue 8, 1996, Pages 1897-1905

  Law, Ronald E ^a   Meehan, Woerner P ^a   Xi, Xiao Ping ^a   Graf, Kristof ^a,d   Wuthrich, Daniel A ^c   Coats, William ^b   Faxon, David ^b   Hsueh, Willa A ^a,e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Department of Medicine   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^e LAC USC MEDICAL CENTER   (United States)

Author keywords

basic fibroblast growth factor; c fos; MAP kinase; platelet derived growth factor; restenosis

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ANIMAL CELL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; HYPERINSULINEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; RAT; RESTENOSIS; VASCULAR SMOOTH MUSCLE;

EID: 0029861097     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118991     Document Type: Article

References (64)

1. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (Lond.). 362:801-809.
2. Gerstendorst, G.R., H.E.J. Seppa, H.K. Kleinman, and G.R. Martin. 1981. Attachment of smooth muscle cells to collagen and their migration toward platelet-derived growth factor. Proc. Natl. Acad. Sci. USA. 78:3669-3672.
3. Ferns, G.A., E.W. Raines, K.H. Sprugel, A.S. Montani, M.A. Reidy, and R. Ross. 1991. Inhibition of neointimal smooth muscle accumulation after angioplasty with an antibody to PDGF. Science (Wash. DC). 253:1129-1132.
4. Jawien, A., D.F. Bowen-Pope, V. Lindner, S.M. Schwartz, and A.W. Clowes. 1992. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J. Clin. Invest. 89:507-511.
5. Bilato, C., R.R. Pauly, G. Metillo, R. Monicone, D. Gorelick-Feldman, Y.A. Gluzband, S.J. Sollot, B. Ziman, E.G. Lakatta, and M.T. Crow. 1995. Intracellular signaling pathways required for rat vascular smooth muscle cell migration. J. Clin. Invest. 96:1905-1915.
6. Lindner, V., D.A. Lappi, A. Baird, R.A. Majack, and M.A. Reidy. 1991. Role of basic fibroblast growth factor in vascular lesion formation. Circ. Res. 68: 106-113.
7. Lindner, V., and M.A. Reidy. 1991. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA. 88:3739-3743.
8. Libby, P., S.J. Warner, R.N. Salmon, and L.K. Birinyi. 1988. Production of platelet-derived growth factor-like mitogen by smooth muscle cells from human atheroma. N. Engl. J. Med. 318:1493-1498.
9. Majesky, M.W., M.A. Reidy, D.F. Bowen-Pope, C.E. Hart, J.N. Wilcox, and S.M. Schwartz. 1990. PDGF ligand and receptor gene expression during repair of arterial injury. J. Cell Biol. 111:2149-2158.
10. Miano, J.M., N. Vlasik, R.R. Tota, and M.B. Stemerman. 1993. Smooth muscle cell immediate-early gene and growth factor activation follows vascular injury. Arterioscler. Thromb. 13:211-219.
11. Morishita, R., G.H. Gibbons, K.E. Ellison, M. Najajima, H. von der Leyen, L. Zhang, Y. Kaneda, T. Ogihara, and V.J. Dzau. 1994. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J. Clin. Invest. 93:1458-1464.
12. Chang, M.W., E. Barr, J. Seltzer, Y.Q. Jian, G.J. Nabel, E.G. Nabel, M.S. Parmacek, and J.M. Leiden. 1995. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science (Wash. DC). 267:518-522.
13. Fujiwara, T., S. Yoshioka, T. Yoshioka, I. Ushiyama, and H. Horikoshi. 1988. Characterization of new oral antidiabetic agent CS-045. Diabetes. 37: 1549-1558.
14. Lee, M.K., D.G. Phillip, M. Khoursheed, K.M. Gao, A.R. Moossa, and J.M. Olefsky. 1994. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes. 43:1435-1439.
15. Eldershaw, T.P.D., S. Rattigan, M.A. Cawthorne, R.E. Buckingham, E.Q. Colquhoun, and M.G. Clark. 1995. Treatment with the thiazolidinedione (BRL 49653) decreased insulin resistance in obese Zucker hindlimb. Horm. Metab. Res. 27:169-172.
16. Iwamato, I., T. Kuzuya, A. Matsuda, S. Kumakura, G. Inooka, and I. Shiraishi. 1991. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 14:1083-1086.
17. Nolan, J.J., B. Ludvik, P. Beerdsen, M. Joyce, and J. Olefsky. 1994. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331:1188-1193.
18. Dubey, R.K., H.Y. Zhang, S.R. Reddy, M.A. Boegehold, and T.A. Kotchen. 1993. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am. J. Physiol. R726-R732.
19. Kortenjann, M., O. Thomae, and P.E. Shaw. 1994. Inhibition of v-raf-dependent c-fos expression and transformation by a kinase-defective mutant of the mitogen-activated protein kinase Erk2. Mol. Cell. Biol. 14:4815-4824.
20. Twentyman, P.R., and M. Luscombe. 1987. A study of some variables in tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br. J. Cancer. 56:279-285.
21. Van de Loosdrecht, A.A., R.H.J. Beelen, G.J. Ossenkoppele, M.G. Broekhoven, and M.M.A.C. Langenhuijsen. 1994. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J. Immunol. Methods. 174:311-320.
22. Chomczynski, P.S., and N. Sacchi. 1989. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
23. Harpold, M.M., R.M. Evans, M. Saidtt-Georgieff, and J.E. Darnell. 1979. Production of mRNA in Chinese hamster cells; relationship of the rate of synthesis to the cytoplasmic concentration of nine specific mRNA sequences. Cell. 17:1025-1035.
24. Sleigh, M.J. 1986. A nonchromatographic assay for expression of the chloramphenicol acetyl transferase gene in eukaryotic cells. Anal. Biochem. 156:251-256.
25. Miller, J.H. 1972. In Experiments in Molecular Genetics. J.H. Miller, editor. Cold Spring Harbor Laboratory, New York. 352-355.
26. Clowes, A.W., M.A. Reidy, and M.M. Clowes. 1983. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab. Invest. 49:327-333.
27. Katuka, T., J.W. Currier, C.C. Haudenschild, T.J. Ryan, and D.P. Faxon. 1994. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation. 89:2809-2815.
28. Lakatta, E.G., E.K. Rowinsky, and J.L. Kinsella. 1995. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J. Clin. Invest. 95:1869-1876.
29. Treisman, R. 1995. Journey to the surface of the cell: Fos regulation and the SRE. EMBO (Eur. Mol. Biol. Organ.) J. 14:4905-4913.
30. Janknecht, R., M.A. Cahil, and A. Nordhem. 1995. Signal integration at the c-fos promoter. Carcinogenesis. 16:443-450.
31. TCF by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature (Lond.). 358:414-417.
32. Gille, H., M. Kortenjann, O. Thomae, C. Moomaw, C. Slaughter, M.H. Cobb, and P.E. Shaw. 1995. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO (Eur. Mol. Biol. Organ.) J. 14:951-962.
33. Gille, H., M. Kortenjann, T. Strahl, and P.E. Shaw. 1996. Phosphorylation-dependent formation of a quaternary complex at the c-fos SRE. Mol. Cell. Biol. 16:1094-1102.
34. Davis, D.J. 1993. The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268:14553-14556.
35. Seger, R., and E.G. Krebs. 1995. The MAPK signaling cascade. FASEB (Fed. Am. Soc. Exp. Biol.) J. 9:726-735.
36. Chen, R.H., C. Sarnecki, and J. Blenis. 1992. Nuclear localization and regulation of ERK-and RSK-encoded protein kinases. Mol. Cell. Biol. 12:915-927.
37. mapk) in fibroblast. J. Cell Biol. 122:1079-1088.
38. Gonzalez, F.A., A. Seth, D.L. Raden, D.S. Bowman, F.S. Fay, and R.J. Davis. 1993. Serum-induced translocation of mitogen activated protein kinase to the cell surface ruffling membrane and the nucleus. J. Cell Biol. 122:1089-1101.
39. Miano, J.M., N. Vlasic, R.R. Torta, and M.B. Stemerman. 1993. Localization of Fos and Jun protein in rat aortic smooth muscle cells after vascular injury. Am. J. Pathol. 142:715-724.
40. Law, R.E., X.P. Xi, and W.A. Hsueh. 1995. Troglitazone inhibits insulin, EGF, and PDGF mitogenic signal transduction in A10 vascular smooth muscle (VSM) and mesangial cells. Hypertension (Dallas). 26:553a. (Abstr.)
41. Geissler, J.F., P. Traxler, U. Regenass, B.J. Murray, J.L. Roesel, T. Myer, E. McGlynn, A. Storni, and N.B. Lydon. 1990. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors. J. Biol. Chem. 285:22255-22281.
42. Kobayashi, M., M. Iwanishi, K. Egawa, and Y. Shigeta, 1992. Pioglitazone increase insulin sensitivity by activating insulin receptor kinase. Diabetes. 41:476-483.
43. Iwanishi, M., and M. Kobayashi. 1993. Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats. Metab. Clin. Exp. 42:1017-1021.
44. Pershadsingh, H.A., J. Szollosi, S. Benson, W.C. Hyun, B.G. Feuerstein, and T.W. Kurtz. 1993. Effects of Ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension (Dallas). 21:1020-1023.
45. Buchanan, T.A., W.P. Meehan, Y.Y. Jeng, D. Yang, T.M. Chan, J.L. Nadler, S. Scott, R.K. Rude, and W.A. Hsueh. 1995. Blood pressure lowering by Pioglitazone. Evidence for a direct vascular effect. J. Clin. Invest. 96:354-360.
46. 2 flux but not mitogenesis. Nature (Lond.). 358:678-681.
47. Alessi, D.R., A. Cuenda, P. Cohen, D.T. Dubley, and A.R. Saltiel. 1995. PD-098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo. J. Biol. Chem. 270:27489-27494.
48. Dudley, D.T., L. Pang, S.J. Decker, A.J. Bridges, and A.R. Saltiel. 1995. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA. 92:7686-7689.
49. Parker, T.G., K.L. Chow, R.J. Schwartz, and M.D. Schneider. 1992. Positive and negative control of the skeletal α-actin promoter in cardiac muscle. J. Biol. Chem. 267:3343-3350.
50. Sandouk, T., D. Reda, and C. Hofmann. 1993. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3-TF442A cells by increasing messenger ribonucleic acid transcript stability. Endocrinology. 133: 352-359.
51. Pauly, R.R., C. Bilato, S.J. Sollott, R. Monticone, P.T. Kelly, E.G. Lakatta, and M.T. Crow. 1995. Role of calcium/calmodulin-dependent protein kinase II in the regulation of vascular smooth muscle cell migration. Circulation. 91:1107-1115.
52. Graf, K., X.-P. Xi, J. Tian, R.E. Law, and W.A. Hsueh. 1996. MAP kinase-activation is involved in angiotensin II and PDGF-directed migration by vascular smooth muscle cell. 50th Scientific Sessions, Council for High Blood Pressure. (Abstr.)
53. Casscells, W., D.A. Kappi, B.B. Olwin, C. Wai, M. Sieman, E.H. Speir, J. Sasse, and A. Baird. 1992. Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors. Proc. Natl. Acad. Sci. USA. 89:7159-7163.
54. Chang, M.W., E. Barr, M.M. Lu, K. Barton, and J.M. Leiden. 1995. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J. Clin. Invest. 96: 2260-2268.
55. Simmons, M., E.R. Edelman, and R.D. Rosenberg. 1994. Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J. Clin. Invest. 93:2351-2356.
56. Zempo, N., N. Koyama, R.D. Kenagy, H.J. Lea, and A.W. Clowes. 1996. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler. Thromb. Vasc. Biol. 16:28-33.
57. Chen, S.J., Y.F. Chen, D.M. Miller, H. Li, and S. Oparil. 1994. Mithramycin inhibits myointimal proliferation after balloon injury of the rat carotid artery in vivo. Circulation. 90:2468-2473.
58. Schwartz, S.M., D. DeBois, and E.R.M. O'Brien. 1995. The intima: soil for atherosclerosis and restenosis. Circ. Res. 77:445-465.
59. Savage, P.J. 1996. Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. Ann. Intern. Med. 124:123-126.
60. Jarrett, R.J., and M.J. Shiplsy. 1988. Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease: putative association via common antecedent. Further evidence from the Whitehall study. Diabetologia. 31:737-740.
61. Hsueh, W.A., R.E. Law, M. Saad, J. Dy, E. Feener, and G. King. 1996. Insulin resistance and macrovascular disease. Curr. Opin. Endocrinol. & Metab. 3:346-354.
62. Stout, R.W. 1990. Insulin and atheroma: 20 year perspective. Diabetes Care. 1:631-654.
63. Banskota, N.K., R. Taub, K. Zellner, and G.L. King. 1989. Insulin, IGF-1 and PDGF interact additively in the activation of protooncogene c-myc and cellular proliferation in cultured BSMC. Mol. Endocrinol. 3:1183-1199.
64. Berkowitz, K., R. Peters, S. Kjos, M. Dunn, A. Xiang, J. Goico, A. Marroquin, S. Azen, and T. Buchanan. 1996. Effects of troglitazone on insulin sensitivity and B-cell function in women with prior gestational diabetes. Diabetes. 45:57A.